![\"\"](\"http:\/\/www.irishtimes.com\/polopoly_fs\/1.1473042.1374616584!\/image\/image.jpg_gen\/derivatives\/box_620_330\/image.jpg\")
Molecules in the field of epigenetics and immuno-oncology, drugs for the treatment of respiratory diseases, new antibodies for inflammatory diseases, new options for the long-term control and prevention of HIV virus infections, treatments for the cure or remission of hepatitis B and C, cell and gene therapies for the treatment of rare diseases, vaccines.<\/p>\n
There is all this in the portfolio that GSK presented to investors yesterday in New York. Drugs and vaccines which, according to the company, have the potential to be "first-in-class" in 80 percent of cases thanks to new mechanisms of action: as a result, they could offer additional benefits compared to current standards of care and could, in some cases, radically transform the way patients are treated.<\/p>\n
The goal of the approval request is not far off for many of them: potentially, twenty of them could come under the scrutiny of the health authorities before 2020, another 20 before 2025.<\/p>\n
\u201cToday we have profiled around 40 potential new medicines and innovative vaccines, which will support the future growth of our business,\u201d said GSK CEO Sir Andrew Witty<\/strong><\/span><\/a>. \u201cMany of these assets are in late and late stages of development and, for the first time, we have also outlined the size of GSK's new opportunities in the early stages of development, specifically in areas such as oncology and immuno-inflammation.\u201d .<\/p>\n DRAFTING NOVEMBER 4, 2015 \u2013 HealthDesk<\/span><\/a><\/p>\n